SPOTLIGHT -
Creating A Successful Social Media Presence
Social media is a great way to gain exposure, but there are many dos-and-don’ts to understand when signing up for a social platform.
Vaxneuvance Approved by FDA for Ages 6 Weeks Through 17 Years
The FDA approved the pneumococcal 15-valent conjugate vaccine for the prevention of invasive pneumococcal disease in infants and children.
Moderna, Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age Authorized by FDA
The FDA announced the EUA of both Moderna and Pfizer-BioNTech COVID-19 vaccines for use in children aged 6 months and older.
PRIORIX Approved by FDA for Measles, Mumps, and Rubella Prevention
GSK plc announced FDA approval of the PRIORIX vaccine for prevention of measles, mumps, and rubella.
Favorable Response to Third Dose of Pfizer-BioNTech Vaccine Noted for Kids 6 Months to 5 Years
Pfizer-BioNTech reports strong immune response, high efficacy, and favorable safety in third dose of the COVID-19 vaccine.
$28 Million Aid Bill for Formula Shortage Proposed in Congress
The proposed aid bill would give the FDA funds to increase staff and prepare for future infant formula shortages.
FDA Gives Increased Flexibility for Foreign Imports of Infant Formula
This week, the agency announced it is encouraging importation of infant formula from usually unutilized foreign means in hopes of increasing access to the product in the wake of the country-wide shortage.
What's Going On with the Infant Formula Shortage
Parents are on edge as the formula shortage worsens across the United States. Pediatricians, the AAP, and White House advise on available options.
Bacterial Resistance Risk With Systemic Antibiotic Use for Acne
At AAD, one researcher shared the potential risks of antibiotic resistance in acne management.
How to Treat Acne in Transgender Patients on Testosterone
Patients on testosterone for masculinizing hormone therapy are at an increased risk of acne due to both inside and outside factors. Matthew David Mansh, MD, FAAD, explains his process for treating these patients.
Upadacitinib Approved for Moderate to Severe Atopic Dermatitis
AbbVie announced the approval after 3 studies show the efficacy and safety of upadacitinib using mono- and combination therapy.
